Jenny Huang
Biographic Data
| ID | 5541255 |
|---|---|
| NAME | Jenny Huang |
| GIVEN NAMES | Jenny |
| FAMILY NAME | Huang |
| SIGNATURE | HUANG J |
| AFFILIATIONS | GlaxoSmithKline (Canada) |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2003 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
Defining the Need for Radiotherapy for Lung Cancer in the General Population
BACKGROUND: We have previously used an evidence-based, epidemiologic approach to estimate the proportion of incident cases that should be treated with radiotherapy (RT) for lung cancer. The first objective of the present study was to compare this evidence-based estimate of the appropriate rate of use of RT with the rates observed in selected "benchmark" communities where there are no barriers to the appropriate use of RT and no incentives to the …
No prominent works on this page.
Defining the Need for Radiotherapy for Lung Cancer in the General Population
BACKGROUND: We have previously used an evidence-based, epidemiologic approach to estimate the proportion of incident cases that should be treated with radiotherapy (RT) for lung cancer. The first objective of the present study was to compare this evidence-based estimate of the appropriate rate of use of RT with the rates observed in selected "benchmark" communities where there are no barriers to the appropriate use of RT and no incentives to the …
Patient-Reported Outcomes in Atlas and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled ana…
Family medicine (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Advances in Oncology and Radiotherapy (1 work) · Adverse effect (1 work) · Antiretroviral therapy (1 work) · Cancer (1 work) · Cancer registry (1 work) · Confidence interval (1 work) · Demography (1 work)